Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

New phase I trial explores use of TLX250-CDx in bladder cancer

June 23, 2021

POLQ is next target for DNA damage response

June 23, 2021

NP-G2-044 shows safety and preliminary antitumor activity in phase I study

June 23, 2021

Lupin synthesizes new SOS1 inhibitors

June 23, 2021

Captor Therapeutics identifies new CRBN-targeting compounds

June 23, 2021

Taiho Pharmaceutical and Astex Therapeutics patent GTPase KRAS inhibitors

June 23, 2021

Phase I dose-escalation data presented for BI-907828 in advanced solid tumors

June 23, 2021

Stimulation of optic nerve activity increases optic glioma growth in mice with Nf1 mutations

June 22, 2021

Lunan Pharmaceutical Group describes oleanane cinnamamide derivatives

June 22, 2021

New GTPase KRAS mutant inhibitors presented by Taiho Pharmaceutical

June 22, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...